Skip to main content
NPCE logo

NeuroPace, Inc. (NPCE) Stock Price & Analysis

NeuroPace, Inc. (NPCE) — MoonshotScore 20/100 (Weak band), calculated Nov 22, 2026. Price $7.95 (-2.33%), as of the Nov 20, 2026 trading session; market cap $274M.

Educational signal · not a buy or sell recommendation · How to read this

$7.95 −$0.19 (-2.33%) Market Cap $274M

NeuroPace, Inc. · NPCE · NASDAQ

NeuroPace, Inc. is a medical device company specializing in the RNS System, a brain-responsive neuromodulation technology for treating medically refractory focal epilepsy. The system delivers personalized, real-time treatment at the seizure source and records continuous brain activity data for clinical monitoring.

Price as of Nov 20, 2026

Key Statistics

20 of 100

MoonshotScore v2 · NeuroPace (NPCE)

Weak
Business Quality Solid (61)
Financial Safety Fragile (17)
Valuation Full (48)
Growth Durability Growing (69)
Momentum Slipping (35)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Durable growth, but a fragile balance sheet and a full valuation. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Fragile; Valuation: Full; Growth Durability: Growing; Momentum: Slipping.

  • EPS beat 6 of the last 8 reports
  • Altman Z -5.00 · Piotroski F 4
  • ROE -97.0% · ROA -6.3% · current ratio 5.26

Holding back: balance-sheet strain

Helping: durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for NPCE (58 recorded, newest six shown)
RecordedScoreBand
19Weak
19Weak
19Weak
19Weak
19Weak
19Weak

The score moved from 19 in the stored Nov 21, 2026 snapshot to 20 in the current publication computed Nov 22, 2026 (+1); the largest pillar moves were Momentum +2 and Valuation +1. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$7.95
Change on the day-2.33%
Market capitalisation$274M
Shares traded on the day749.4K

Price & events

Other perspectives

Council score for NeuroPace (NPCE): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Negative
Valuation Neutral
Growth Durability Moderate
Momentum Weak

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 22, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Negative
ROE Negative
Gross Margin Strong

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is NeuroPace (NPCE), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. NeuroPace, Inc. (NPCE) is listed on NASDAQ. It employs 216 people. The market values it at $274M.

2 · Latest results

What do the latest results show for NeuroPace (NPCE)?

Short answer · as of

Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$23M-$3M-$0.11 (diluted)
Q4 FY2025$27M-$3M-$0.08 (diluted)
Q1 FY2026$22M-$7M-$0.20 (diluted)
Q2 FY2026$23M-$6M-$0.18 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for NeuroPace (NPCE)?

Short answer

The MoonshotScore pillars rate durable growth as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -5.00 · Piotroski F 4. Trailing ratios: ROE -97.0% · ROA -6.3% · current ratio 5.26.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -5.00 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-97.0%) — the business is not currently generating profit on shareholder capital.
4 · What to check next?

What should you watch next at NeuroPace (NPCE)?

Short answer · as of

The stored analyst-target capture is expired, so a current target watchpoint is unavailable.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does NeuroPace compare with its peers?

Short answer

NeuroPace's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Delcath Systems, Inc. (DCTH) Same industry, near in market value$18.79 Nov 20, 2026$654M94 5-pillar Nov 22, 2026
InMode Ltd. (INMD) Same industry, near in market value$12.42 Nov 20, 2026$715M93 5-pillar Nov 22, 2026
Tactile Systems Technology, Inc. (TCMD) Same industry, near in market value$25.60 Nov 20, 2026$573M90 5-pillar Nov 22, 2026
Viemed Healthcare, Inc. (VMD) Same industry, near in market value$8.52 Nov 20, 2026$323M88 5-pillar Nov 22, 2026
Electromed, Inc. (ELMD) Same industry, near in market value$22.98 Nov 20, 2026$188M88 5-pillar Nov 22, 2026
BrainsWay Ltd. (BWAY) Same industry, near in market value$8.48 Nov 20, 2026$333M86 5-pillar Nov 22, 2026
Bioventus Inc. (BVS) Same industry, near in market value$9.88 Nov 20, 2026$677M80 5-pillar Nov 22, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.23 Nov 20, 2026$177M72 5-pillar Nov 22, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.30 Nov 20, 2026$138M37 5-pillar Nov 22, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.07 Nov 20, 2026$247M36 5-pillar Nov 22, 2026
908 Devices Inc. (MASS) Same industry, near in market value$8.67 Nov 20, 2026$361M35 5-pillar Nov 22, 2026
Sight Sciences, Inc. (SGHT) Same industry, near in market value$10.18 Nov 20, 2026$566M34 5-pillar Nov 22, 2026
NeuroPace (NPCE) — this page$7.95$274M20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
$12.00 – $21.00
Last captured analyst target (expired, captured Nov 18, 2026)
$15.67
Last captured median analyst target (expired, captured Nov 18, 2026)
$14.00

Historical target record · Captured · Capture expired; not a current watchpoint.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NPCE in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported NPCE in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about NeuroPace (NPCE)?

Read these with our analysis →

Investor Questions: NPCE Stock

These answers are editorial: 1 of these 9 answers is drawn from the NPCE research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for NPCE?

NPCE carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is NPCE a good stock to buy?

Stock Expert AI does not rate NPCE buy, sell or hold. NeuroPace, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the NPCE stock price today?

The last price recorded for NeuroPace, Inc. (NPCE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the NPCE price target?

The last analyst consensus price target we captured for NeuroPace, Inc. (NPCE), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.

What does NeuroPace, Inc. do?

NeuroPace, Inc. is a medical device company that develops and commercializes the RNS System, an advanced brain-responsive neuromodulation system. This system is specifically designed to treat medically refractory focal epilepsy, a condition where seizures are not controlled by medication.

What are the key factors to evaluate for NPCE?

NeuroPace, Inc. (NPCE) holds a MoonshotScore in the low range. Despite the RNS System's FDA approval, a substantial portion of eligible patients may not yet be aware of or have access to this treatment option. Not financial advice.

How frequently does NPCE data refresh on this page?

NPCE's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven NPCE's recent stock price performance?

NeuroPace, Inc. (NPCE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary RNS System offers a unique, brain-responsive treatment for focal epilepsy. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider NPCE overvalued or undervalued right now?

NeuroPace, Inc. (NPCE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 9 from Financial Modeling Prep (FMP), 3 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.